CHARLES WYKOFF to Geographic Atrophy
This is a "connection" page, showing publications CHARLES WYKOFF has written about Geographic Atrophy.
Connection Strength
6.512
-
Syfovre Approval for Geographic Atrophy. JAMA Ophthalmol. 2024 Jul 01; 142(7):685-686.
Score: 0.893
-
Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr Opin Ophthalmol. 2024 Jan 01; 35(1):64-72.
Score: 0.849
-
Diagnosis and Management of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Delphi Consensus Exercise. Ophthalmic Surg Lasers Imaging Retina. 2023 10; 54(10):589-598.
Score: 0.848
-
Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
Score: 0.735
-
Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration. BioDrugs. 2021 May; 35(3):303-323.
Score: 0.716
-
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology. 2021 09; 128(9):1325-1336.
Score: 0.710
-
Topographic analysis of local OCT biomarkers which predict progression to atrophy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024 Jul; 262(7):2083-2091.
Score: 0.217
-
The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis. Surv Ophthalmol. 2024 May-Jun; 69(3):349-361.
Score: 0.214
-
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 10 21; 402(10411):1434-1448.
Score: 0.213
-
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 10 21; 402(10411):1449-1458.
Score: 0.211
-
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 12; 37(17):3551-3557.
Score: 0.204
-
Re: Minimizing risks to patients by improving presentation of clinical trial results in geographic atrophy trials (Ophthalmol Retina. 2022;6:337-338). Ophthalmol Retina. 2022 11; 6(11):1109.
Score: 0.199
-
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial. JAMA Ophthalmol. 2021 May 01; 139(5):542-547.
Score: 0.179
-
Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials. Ophthalmology. 2020 06; 127(6):769-783.
Score: 0.163
-
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 02; 127(2):186-195.
Score: 0.158